Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?

Hims & Hers reported Q1 2026 revenue of $608.1 million, up 4% year over year, but profitability weakened sharply with a $92.1 million net loss versus $49.5 million net income a year ago and adjusted EBITDA down to $44.3 million from $91.1 million. Gross margin compressed to 65% from 73% as the company shifted away from compounded GLP-1 drugs toward branded therapies, while management cut full-year adjusted EBITDA guidance to $275 million-$350 million from $300 million-$375 million even as revenue guidance was raised to $2.8 billion-$3.0 billion. Shares fell more than 12% on the report, though operating cash flow remained positive at $89.4 million and free cash flow was $53 million.

Analysis

The market is repricing HIMS from a high-margin compounding story into a lower-margin regulated distribution business. That transition matters more than the headline revenue beat: once the company leans into branded GLP-1s, diagnostics, and international fulfillment, it starts competing less on software-like unit economics and more on customer acquisition efficiency, supplier terms, and regulatory execution. In other words, the multiple should compress unless management proves that gross margin can stabilize above the low-60s while growth stays above 25-30%.

Near term, the key risk is that spend ramps before new revenue streams are mature. International expansion and M&A are likely to create a 2-3 quarter drag on EBITDA, and if weight-loss mix remains the largest growth engine, any incremental pressure from branded drug pricing will hit margins twice: once through product economics and again through higher marketing intensity to maintain subscriber growth. That sets up a classic “good top line, bad incrementals” pattern that tends to persist for several quarters, not days.

The contrarian angle is that the selloff may still be incomplete if investors are anchoring to the prior margin structure. HIMS can absolutely grow into a broader digital-health platform, but the probability-weighted path looks more like an evolving consumer healthcare distributor than a software compounder, which is a fundamentally lower terminal multiple. By contrast, NVO is a quiet beneficiary if branded adoption expands, because HIMS is effectively helping normalize a premium channel for obesity drugs without owning the physician relationship itself.

The stock is likely to trade on execution milestones rather than next-quarter revenue: margin stabilization, international contribution, and evidence that AI/diagnostics raise lifetime value enough to offset CAC inflation. Until then, the burden of proof is on management, and the premium valuation remains vulnerable to any slowdown in subscriber additions or another cut to EBITDA guidance.

Key Decisions for Investors

• Short HIMS on strength into earnings-driven relief rallies; 3-6 month horizon, with downside catalyzed by another quarter of margin compression or guidance cuts. Best risk/reward if entry is above the post-gap range and target is a retrace toward pre-earnings valuation support.
• Pair trade: long NVO / short HIMS for 1-2 quarters. If branded GLP-1 share gains accelerate, NVO captures economics with lower execution risk while HIMS absorbs the CAC and fulfillment burden; this isolates the margin-compression trade from broader obesity-drug demand.
• Avoid chasing HIMS until gross margin stabilizes for at least two consecutive quarters. A sustained hold above the mid-60s would be the first credible sign that the business mix is normalizing; before that, the stock remains a momentum-dependent trade, not a fundamentals compounder.
• Sell out-of-the-money HIMS puts 60-90 days out only if implied volatility remains elevated; the thesis is that the market is overpaying for downside protection, but the trade should be sized conservatively because further guidance reductions would quickly overwhelm theta.
• If looking for a cleaner long exposure to digital health, wait for evidence that international revenue is accretive rather than dilutive. Otherwise, the better trade is to own the supplier/brand side of the obesity stack rather than the regulated distributor.